TWST releases biotech investment report

The Wall Street Transcript has published a Biotechnology Report offering a review of the sector to serious investors and industry executives. The  107-page feature contains expert industry commentary through in-depth  interviews with public company chief executives, equity analysts and  money managers.

Topics covered include: Autologous Stem Cell Transplants; Significant  Barriers to Entry; R&D spending outlook; M&A activity; Potential  acquisition targets; Big Pharma interest in acquisitions; FDA approval  process; Missed PDUFA dates; Molecular diagnostics growth area;  Follow-on biologics; Activist shareholder action; Cost containment  measures; More generic drug usage; IPO window; Shortage of cash;  Expectation of more bankruptcies; Winners and losers; Investor interest;  and Stocks picks, for companies such as: Genzyme; Celgene; Gilead  Sciences; Medivation; Sequenom; XenoPort; Biogen Idec; Dendreon; Acorda  Therapeutics; Vertex Pharmaceuticals; Amylin Pharmaceuticals; BioMarin  Pharmaceuticals; and Myriad Genetics.

The full report is available from: www.twst.com